ARA-290 vs Cerebrolysin
Overview
ARA-290 and Cerebrolysin are both pain management peptides, but they differ in mechanism, dosing, and regulatory status.
This page compares ARA-290 and Cerebrolysin across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| ARA-290 | Cerebrolysin | |
|---|---|---|
| Category | Pain Management | Pain Management |
| Regulatory status (US) | Research use only | Research use only |
| Typical dosage | 2-4 mg | 5-10 ml |
| Frequency | daily for cycles | multiple weekly |
| Reported benefits | Neuropathic pain reduction, nerve protection, diabetic neuropathy support | Nerve pain reduction, neuroprotection, stroke pain support |
| Reported side effects | Generally well-tolerated | Generally well-tolerated |
Key differences
Primary use. ARA-290 is categorised under Pain Management, while Cerebrolysin falls under Pain Management. Because they target a similar goal, they are common alternatives to weigh against each other.
Regulatory status. ARA-290: not FDA-approved; treated as a research compound. Cerebrolysin: not FDA-approved; treated as a research compound.
Dosing. ARA-290 is typically dosed at 2-4 mg (daily for cycles). Cerebrolysin is typically dosed at 5-10 ml (multiple weekly).
Can you stack them?
Some protocols combine peptides, but stacking ARA-290 and Cerebrolysin has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between ARA-290 and Cerebrolysin?
- ARA-290 and Cerebrolysin are both pain management peptides, but they differ in mechanism, dosing, and regulatory status. ARA-290 is not FDA-approved; generally classified as a research compound, whereas Cerebrolysin is not FDA-approved; generally classified as a research compound.
- What is ARA-290 used for?
- Neuropathic pain specialist.
- What is Cerebrolysin used for?
- Neuropathic pain support.
- Can you take ARA-290 and Cerebrolysin together?
- Some users combine peptides within a single protocol, but stacking ARA-290 and Cerebrolysin has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is ARA-290 or Cerebrolysin FDA-approved?
- ARA-290 is not FDA-approved; generally classified as a research compound. Cerebrolysin is not FDA-approved; generally classified as a research compound.
Read the full articles
- ARA-290 — full monograph: mechanism, research, dosing & references
- Cerebrolysin — full monograph: mechanism, research, dosing & references